This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Guidant Stent Approved in EU

Medical-device maker Guidant (GDT) said regulators for the European Union nations approved its new stent earlier than had been expected.

Approval by the European Union allows Guidant to market its Xience V stent system as a treatment for coronary artery disease. The stent is used to prop open clogged arteries and is coated with everolimus, a drug that prevents reclogging. The device will be ready for launch in the second quarter, Guidant said Monday.

"This early approval represents a significant milestone in Guidant's drug-eluting stent program and demonstrates our ongoing commitment to advancing the field of cardiovascular therapy through innovative solutions," said John Capek, president of Guidant's vascular intervention business.

Guidant, which also manufactures pacemakers and defibrillators, has been under fire since thousands of its devices were recalled last year. The Indianapolis-based company agreed to be acquired by another stent maker, Boston Scientific (BSX - Get Report), following a bidding war with Johnson & Johnson (JNJ) for the troubled company.

Guidant's shares fell $1.39 to $72.33 near the market close Monday. Shares of Boston Scientific were down 84 cents, or 3.8%, to $20.80.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BSX $16.11 -3.80%
AAPL $107.76 -4.40%
FB $87.23 -2.50%
GOOG $598.06 -3.30%
TSLA $238.68 -4.20%

Markets

Chart of I:DJI
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,914.07 -58.11 -2.95%
NASDAQ 4,636.1050 -140.4030 -2.94%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs